Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

✍ Scribed by Francis J. Giles; Hagop M. Kantarjian; Steve M. Kornblau; Deborah A. Thomas; Guillermo Garcia-Manero; Tracey A. Waddelow; Cynthia L. David; Alexandria T. Phan; Dawn E. Colburn; Asif Rashid; Elihu H. Estey

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 483 KB
• Volume: 92
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u